- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02970175
Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy (TERLAB)
The diagnostic yield of flexible bronchoscopy for the diagnosis of lung cancer depends on the location and the histological type of the lesion, as well as on the number of biopsy samples performed. The increasing number of sampling is also important to provide material for molecular assessment of lung cancer. The French National Institute for Cancer recommends a number of 5 biopsies in order to reach a diagnostic yield of 88%. However, as increasing the number of bronchial biopsies comes with a higher risk of bleeding, the management of endobronchial bleeding may be determinant for the diagnostic yield.
The most recent recommendations of the British Thoracic Society for the management of bronchial bleeding, after bronchial or transbronchial biopsy, are to inject 5 to 10 mL of 1/10000 diluted adrenalin, or cold saline serum (04°C.). The French guidelines also include the use of endobronchial terlipressin, which has local vasoconstriction effect. After endobronchial administration of terlipressin, plasmatic concentrations are low, and are not clinically relevant.
The hypothesis of this clinical trial is that endobronchial instillation of terlipressin before sampling endobronchial tumor will limit the endobronchial bleeding and allow to increase the number of biopsies performed and, eventually, the diagnostic yield.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Mathieu SALAUN, MD
- Phone Number: 8265 +3323288
- Email: mathieu.salaun@chu-rouen.fr
Study Locations
-
-
-
Rouen, France
- Recruiting
- ROUEN university hospital
-
Contact:
- Mathieu SALAUN, MD
-
Principal Investigator:
- Mathieu SALAUN, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients ≥18 years old
- Patients scheduled to undergo bronchoscopy, presenting a suspicious radiographic lesion and a lesion proximal tumor pace viewable in white light endoscopy and without pathologic diagnosis
- Patient having read and understood the information letter and signed the consent form
- Effective contraception in women of childbearing age
Exclusion Criteria:
- Patients with contraindication to the use of terlipressin:
- septic shock ,
- Hypersensitivity to terlipressin or the excipients or by whom use the product is not recommended:
- Recent history (<3 months) of acute coronary syndrome (including myocardial infarction) or unbalanced coronary insufficiency, or disorders of the ventricular heart rate.
- severe uncontrolled hypertension,
- cerebrovascular insufficiency and ischemic stroke of recent origin (<3 months).
- severe arterial occlusive lower extremities,
- severe chronic renal impairment (GFR <20 ml / min).
- Patients receiving uninterrupted antiplatelet therapy during 5 days before endoscopy (7 days for Clopidogrel Related), including low dose aspirin (≤ 75 mg / day).
- Patients receiving anticoagulant therapy:
- Unfractionated heparin within 12 hours before endoscopy.
- low molecular weight heparin within 24 hours before endoscopy.
- Patients with bleeding disorders defined by TP below 70% or TCA ratio patient / control greater than 1.3.
- Patients with thrombocytopenia less than 100 g / L.
- Subjects misunderstanding of spoken and written French
- Person under guardianship or deprived of liberty by judicial or administrative decision (under Article L1121-6 and L1121-8 of Public Health Code
- Pregnant or lactating women, premenopausal women without adequate contraception
- Patient participating in other drug testing or participating in another drug test in the previous month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bronchoscopy with terlipressin administration
Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions.
Bronchoscopy will be done with terlipressin administration
|
Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions.
Bronchoscopy will be done with terlipressin administration
Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions.
Bronchoscopy will be done with terlipressin administration
Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions.
Bronchoscopy will be done with terlipressin administration
|
Placebo Comparator: Bronchoscopy without terlipressin administration
Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions.
Bronchoscopy will be done without terlipressin administration
|
Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions.
Bronchoscopy will be done with terlipressin administration
Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions.
Bronchoscopy will be done with terlipressin administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of biopsy realized during the endoscopy
Time Frame: Day 1
|
The number of biopsy by endoscopy realized into each group will be calculated
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of biopsy allowing an histological diagnosis
Time Frame: Day 1
|
The number of biopsy allowing an histological diagnosis into each group will be calculated
|
Day 1
|
Number of adverse events due to terlipressin administration
Time Frame: Day 1
|
Day 1
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014/212/HP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchial Endoscopy
-
Centre Hospitalier Universitaire DijonTerminatedPatient With Bronchial EndoscopyFrance
-
Buddhist Tzu Chi General HospitalUnknownMethods of Nasal Anesthesia Before Transnasal Endoscopy | Side Effects of Transnasal Endoscopy | Patient's Tolerance to Transnasal EndoscopyTaiwan
-
Fujifilm Medical Systems USA, Inc.Completed
-
Children's Mercy Hospital Kansas CityCompletedEndoscopyUnited States
-
State University of New York - Upstate Medical...Completed
-
Tabriz UniversityCompleted
-
University of NebraskaChildren's Hospital and Medical Center, Omaha, NebraskaCompleted
-
Tongji HospitalRecruitingBidirectional EndoscopyChina
-
Stanford UniversityRecruitingEndoscopy | ColonoscopyUnited States
Clinical Trials on Terlipressin administration
-
University of Roma La SapienzaCompleted
-
First Affiliated Hospital, Sun Yat-Sen UniversityCompleted
-
MallinckrodtCompletedHepatorenal SyndromeUnited States
-
Ferring PharmaceuticalsCompletedGastrointestinal Bleeding | Oesophageal VaricesRomania
-
Pere GinesUnknownCirrhosis | Hepatorenal Syndrome Type ISpain
-
Assaf-Harofeh Medical CenterUnknown
-
BioVie Inc.CompletedCirrhosis | Ascites HepaticUnited States
-
Aga Khan UniversityFerozsons Laboratories Ltd.CompletedHemorrhage | Portal Hypertension | Esophageal VaricesPakistan
-
Hospital Clinic of BarcelonaGrant from Education Ministery from 2001-2004.SuspendedCirrhosis | Hepatorenal SyndromeSpain
-
Aga Khan UniversityMallinckrodtUnknown